Geron Corp - Company Profile
Powered by 
All the sales intelligence you need on Geron Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Geron Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Geron Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Geron Corp (Geron) is a biopharmaceutical company. It is focused on developing therapies to enhance the lives of patients with hematologic malignancies. Its product portfolio includes the investigational telomerase inhibitor, imetelstat, which was approved by the US Food and Drug Administration (FDA) as Rytelo for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) characterized by transfusion-dependent anemia. Geron's products are primarily used by healthcare providers to treat adult patients with specific types of blood cancer, such as myelodysplastic syndromes. The company is also advancing imetelstat in multiple myeloid malignancies, including various clinical trials targeting high-risk myelofibrosis; combination therapies and higher-risk MDS and acute myeloid leukemia. Geron is headquartered in Foster City, California, US.
Headquarters
United States of America
Address
Suite 250, 919 East Hillsdale Boulevard, Foster City, California, 94404
Website
www.geron.com
Telephone
1 650 4737700
No of Employees
258
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GERN (NASD)
Revenue (2024)
$183.9M
138.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
52.2%
(2024 vs 2023)
Market Cap*
$790.2M
Net Profit Margin (2024)
XYZ
80.0%
(2024 vs 2023)
* As of and is in US$
Geron Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Products | Rytelo |
| Imetelstat: Low- to Intermediate-1 Risk Myelodysplastic Syndromes | |
| Pipeline: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Asset Disposal | In November, the company sold a synthetic royalty on Rytelo to Royalty Pharma, a private equity firm. |
| 2024 | Regulatory Approval | In June, the company received US Food and Drug Administration approval for Rytelo (imetelstat) to treat adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS). |
| 2023 | Official Trials/Tests | In April, the company announced positive top-line results of its product Imetelstat from IMerge Phase 3 Trial. |
Competitor Comparison
| Key Parameters | Geron Corp | Incyte Corp | Kura Oncology Inc | Kyntra Bio Inc | Novartis Pharmaceuticals Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Foster City | Wilmington | San Diego | San Francisco | East Hanover |
| State/Province | California | Delaware | California | California | New Jersey |
| No. of Employees | 258 | 2,844 | 260 | 34 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Elizabeth G. O’Farrell | Chairman | Executive Board | 2025 | 61 |
| Harout Semerjian | Director; President; Chief Executive Officer | Executive Board | 2025 | 55 |
| Michelle Robertson | Executive Vice President; Chief Financial Officer; Treasurer; | Senior Management | 2023 | 59 |
| Timothy Williams | Secretary; Chief Legal Officer; Executive Vice President | Senior Management | 2026 | - |
| Shannon T. Odam | Chief People Officer; Senior Vice President | Senior Management | 2025 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer